Patents by Inventor Bjorn Victor

Bjorn Victor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CTLA4 binders
    Patent number: 11649290
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: May 16, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, Robert A. Kastelein
  • CTLA4 BINDERS
    Publication number: 20200157220
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Application
    Filed: November 27, 2019
    Publication date: May 21, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JUHA PUNNONEN, MARIBEL BEAUMONT, MARIE-ANGE BUYSE, CARLO BOUTTON, BRUNO DOMBRECHT, BJORN VICTOR
  • PD1/CTLA4 binders
    Patent number: 10544222
    Abstract: The present invention provides multispecific molecules, e.g., comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: January 28, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Juha Punnonen, Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, David Vlerick, Robert A. Kastelein
  • CTLA4 binders
    Patent number: 10501542
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: December 10, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, Robert A. Kastelein
  • PD1/CTLA4 BINDERS
    Publication number: 20170137520
    Abstract: The present invention provides multispecific molecules, e.g., comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Application
    Filed: November 17, 2016
    Publication date: May 18, 2017
    Inventors: Juha Punnonen, Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, David Vlerick
  • CTLA4 BINDERS
    Publication number: 20170137521
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Application
    Filed: November 17, 2016
    Publication date: May 18, 2017
    Inventors: Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor